ADMA Biologics Inc. logo

ADMA Biologics Inc.

ADMA | NASDAQ
Chart Builder DCF Calculator
$9.51
+$0.40 (+4.39%)
At close: Sep 21, 2026, 4:00 PM ET
$9.54
+$0.03 (+0.32%)
After-hours: Sep 21, 2026, 7:53 PM ET

Market Data

Market Cap
$2.11B
Enterprise Value
$2.27B
Beta
0.77
Average Volume
4.45M
Shares Outstanding (Diluted)
230.34M
Shares Change YoY
-7.35%
Institutional Ownership
89.78%
Exchange
NASDAQ
ISIN
US0008991046

Price Performance

Price Change 1M
-3.0%
Price Change 3M
9.4%
Price Change 6M
-1.3%
Price Change YTD
-46.8%
Price Change 1Y
-40.7%
Price Change 3Y
170.9%
Price Change 5Y
660.8%
1M CAGR (ann.)
-9.4%
1Y CAGR (ann.)
-41.5%
5Y CAGR (ann.)
50.2%
All-Time CAGR
0.5%

Valuation

PE Ratio
13.59
Forward PE
9.48
PEG Ratio
-0.73
Forward PEG
0.69
PS Ratio
4.30
Forward PS
3.50
PB Ratio
5.40
P/FCF Ratio
18.91
P/Adj. FCF Ratio
23.54
P/OCF Ratio
15.85
EV/Sales
4.43
EV/EBIT
10.08
EV/EBITDA
9.67
EV/FCF
19.50
Earnings Yield
7.4%
FCF Yield
5.3%
Adj. FCF Yield
4.3%

Financial Health

Net Debt
$60.57M
Total Debt
$203.84M
Cash & Short-Term Investments
$136.02M
Total Assets
$684.21M
Current Ratio
6.97
Quick Ratio
3.81
Debt / Equity Ratio
0.50
Debt / EBITDA
0.87
Debt / FCF
1.75
OCF / Debt
0.67
Interest Coverage
24.53
Altman Z-Score
7.06
Piotroski F-Score
5

Margins & Profitability

Gross Profit Margin
64.7%
Operating Profit Margin
42.3%
EBITDA Margin
45.8%
Net Profit Margin
33.0%
FCF Margin
22.7%
Adj. FCF Margin
18.3%
SBC / Revenue
4.5%
SBC Impact (per share)
-19.7%

Returns

Return on Assets
24.7%
Return on Equity
39.6%
Return on Invested Capital
27.6%
Return on Capital Employed
35.6%
Return on Tangible Assets
24.8%

Historical Growth (CAGR)

Revenue CAGR 3Y
35.0%
Revenue CAGR 5Y
54.5%
Revenue CAGR 10Y
50.2%
EPS CAGR 3Y
49.4%
EPS CAGR 5Y
176.0%
EPS CAGR 10Y
56.4%
FCF CAGR 3Y
30.0%
FCF CAGR 5Y
278.1%
FCF CAGR 10Y
63.6%

Analyst Forecasts

Analyst Rating
Buy
Analyst Count
10
EPS Growth Next 3Y
26.6%
Revenue Growth Next 3Y
17.8%
Earnings Date
Nov 3, 2026
EPS Estimate (next Q)
$0.19
EPS Growth Est (next Q)
18.8%
Revenue Est (next Q)
$138.12M
Revenue Growth Est (next Q)
2.9%

Fair Value Estimates

Graham Number
$5.31
Graham Upside
-44.2%
Lynch Fair Value
$17.50
Lynch Upside
84.0%
Price Target
$18.67
Price Target Upside
96.3%

Cash Flow

Operating Cash Flow
$136.72M
Free Cash Flow
$116.47M
Adj. Free Cash Flow
$93.57M
FCF Per Share
$0.51
OCF Per Share
$0.60
OCF/S Ratio
26.7%

Income Statement

Revenue
$512.28M
Gross Profit
$331.47M
Operating Income
$216.5M
EBITDA
$234.83M
Net Income
$168.96M
EPS (Diluted)
$0.70
Revenue / Employee
$795.46K
Profit / Employee
$262.36K
Employees
644

© 2026 bestshares.com. All rights reserved.